Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3	ARRY-520 Sensitive: C3 – Early Trials ARRY-520 Sensitive : C3
CD123 positive	Hodgkin Lymphoma	CD123 positive	Hodgkin Lymphoma	VIP943 Sensitive: D – Preclinical VIP943 Sensitive : D	VIP943 Sensitive: D – Preclinical VIP943 Sensitive : D
CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	VIP943 Sensitive: D – Preclinical VIP943 Sensitive : D	VIP943 Sensitive: D – Preclinical VIP943 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ponatinib + SB-715992 Sensitive: D – Preclinical ponatinib + SB-715992 Sensitive : D	ponatinib + SB-715992 Sensitive: D – Preclinical ponatinib + SB-715992 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	cabozantinib tablet + SB-715992 Sensitive: D – Preclinical cabozantinib tablet + SB-715992 Sensitive : D	cabozantinib tablet + SB-715992 Sensitive: D – Preclinical cabozantinib tablet + SB-715992 Sensitive : D
CXCR5 overexpression	Lymphoma	CXCR5 overexpression	Lymphoma	VIP924 Sensitive: D – Preclinical VIP924 Sensitive : D	VIP924 Sensitive: D – Preclinical VIP924 Sensitive : D

KIF11 inhibitor

KIF11 inhibitor

Associations(7)

Associations
(7)